The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Lacosamide (INN, formerly known as erlosamide, harkeroside, SPM 927, or ADD 234037), is a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. It is marketed under the trade name Vimpat.
The global Lacosamide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Lacosamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Lacosamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Lacosamide in Adults is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Lacosamide include UCB, Teva, Amneal Pharmaceuticals, MSN Laboratories, Alembic Pharma, Glenmark, Aurobindo Pharma, Accord Healthcare and Mylan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Lacosamide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lacosamide.
Report Scope
The Lacosamide market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lacosamide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lacosamide companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
UCB
Teva
Amneal Pharmaceuticals
MSN Laboratories
Alembic Pharma
Glenmark
Aurobindo Pharma
Accord Healthcare
Mylan
Sun Pharma
Apotex
Segment by Type
Oral tablets
Oral solution
Intravenous
Segment by Application
Adults
Pediatric patients
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lacosamide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Lacosamide (INN, formerly known as erlosamide, harkeroside, SPM 927, or ADD 234037), is a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. It is marketed under the trade name Vimpat.
The global Lacosamide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Lacosamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Lacosamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Lacosamide in Adults is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Lacosamide include UCB, Teva, Amneal Pharmaceuticals, MSN Laboratories, Alembic Pharma, Glenmark, Aurobindo Pharma, Accord Healthcare and Mylan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Lacosamide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lacosamide.
Report Scope
The Lacosamide market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lacosamide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lacosamide companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
UCB
Teva
Amneal Pharmaceuticals
MSN Laboratories
Alembic Pharma
Glenmark
Aurobindo Pharma
Accord Healthcare
Mylan
Sun Pharma
Apotex
Segment by Type
Oral tablets
Oral solution
Intravenous
Segment by Application
Adults
Pediatric patients
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lacosamide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lacosamide Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral tablets
1.2.3 Oral solution
1.2.4 Intravenous
1.3 Market by Application
1.3.1 Global Lacosamide Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Adults
1.3.3 Pediatric patients
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lacosamide Market Perspective (2019-2030)
2.2 Lacosamide Growth Trends by Region
2.2.1 Global Lacosamide Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Lacosamide Historic Market Size by Region (2019-2024)
2.2.3 Lacosamide Forecasted Market Size by Region (2025-2030)
2.3 Lacosamide Market Dynamics
2.3.1 Lacosamide Industry Trends
2.3.2 Lacosamide Market Drivers
2.3.3 Lacosamide Market Challenges
2.3.4 Lacosamide Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lacosamide Players by Revenue
3.1.1 Global Top Lacosamide Players by Revenue (2019-2024)
3.1.2 Global Lacosamide Revenue Market Share by Players (2019-2024)
3.2 Global Lacosamide Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lacosamide Revenue
3.4 Global Lacosamide Market Concentration Ratio
3.4.1 Global Lacosamide Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lacosamide Revenue in 2023
3.5 Lacosamide Key Players Head office and Area Served
3.6 Key Players Lacosamide Product Solution and Service
3.7 Date of Enter into Lacosamide Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lacosamide Breakdown Data by Type
4.1 Global Lacosamide Historic Market Size by Type (2019-2024)
4.2 Global Lacosamide Forecasted Market Size by Type (2025-2030)
5 Lacosamide Breakdown Data by Application
5.1 Global Lacosamide Historic Market Size by Application (2019-2024)
5.2 Global Lacosamide Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Lacosamide Market Size (2019-2030)
6.2 North America Lacosamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Lacosamide Market Size by Country (2019-2024)
6.4 North America Lacosamide Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lacosamide Market Size (2019-2030)
7.2 Europe Lacosamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Lacosamide Market Size by Country (2019-2024)
7.4 Europe Lacosamide Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lacosamide Market Size (2019-2030)
8.2 Asia-Pacific Lacosamide Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Lacosamide Market Size by Region (2019-2024)
8.4 Asia-Pacific Lacosamide Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lacosamide Market Size (2019-2030)
9.2 Latin America Lacosamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Lacosamide Market Size by Country (2019-2024)
9.4 Latin America Lacosamide Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lacosamide Market Size (2019-2030)
10.2 Middle East & Africa Lacosamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Lacosamide Market Size by Country (2019-2024)
10.4 Middle East & Africa Lacosamide Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 UCB
11.1.1 UCB Company Detail
11.1.2 UCB Business Overview
11.1.3 UCB Lacosamide Introduction
11.1.4 UCB Revenue in Lacosamide Business (2019-2024)
11.1.5 UCB Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Lacosamide Introduction
11.2.4 Teva Revenue in Lacosamide Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Amneal Pharmaceuticals
11.3.1 Amneal Pharmaceuticals Company Detail
11.3.2 Amneal Pharmaceuticals Business Overview
11.3.3 Amneal Pharmaceuticals Lacosamide Introduction
11.3.4 Amneal Pharmaceuticals Revenue in Lacosamide Business (2019-2024)
11.3.5 Amneal Pharmaceuticals Recent Development
11.4 MSN Laboratories
11.4.1 MSN Laboratories Company Detail
11.4.2 MSN Laboratories Business Overview
11.4.3 MSN Laboratories Lacosamide Introduction
11.4.4 MSN Laboratories Revenue in Lacosamide Business (2019-2024)
11.4.5 MSN Laboratories Recent Development
11.5 Alembic Pharma
11.5.1 Alembic Pharma Company Detail
11.5.2 Alembic Pharma Business Overview
11.5.3 Alembic Pharma Lacosamide Introduction
11.5.4 Alembic Pharma Revenue in Lacosamide Business (2019-2024)
11.5.5 Alembic Pharma Recent Development
11.6 Glenmark
11.6.1 Glenmark Company Detail
11.6.2 Glenmark Business Overview
11.6.3 Glenmark Lacosamide Introduction
11.6.4 Glenmark Revenue in Lacosamide Business (2019-2024)
11.6.5 Glenmark Recent Development
11.7 Aurobindo Pharma
11.7.1 Aurobindo Pharma Company Detail
11.7.2 Aurobindo Pharma Business Overview
11.7.3 Aurobindo Pharma Lacosamide Introduction
11.7.4 Aurobindo Pharma Revenue in Lacosamide Business (2019-2024)
11.7.5 Aurobindo Pharma Recent Development
11.8 Accord Healthcare
11.8.1 Accord Healthcare Company Detail
11.8.2 Accord Healthcare Business Overview
11.8.3 Accord Healthcare Lacosamide Introduction
11.8.4 Accord Healthcare Revenue in Lacosamide Business (2019-2024)
11.8.5 Accord Healthcare Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Lacosamide Introduction
11.9.4 Mylan Revenue in Lacosamide Business (2019-2024)
11.9.5 Mylan Recent Development
11.10 Sun Pharma
11.10.1 Sun Pharma Company Detail
11.10.2 Sun Pharma Business Overview
11.10.3 Sun Pharma Lacosamide Introduction
11.10.4 Sun Pharma Revenue in Lacosamide Business (2019-2024)
11.10.5 Sun Pharma Recent Development
11.11 Apotex
11.11.1 Apotex Company Detail
11.11.2 Apotex Business Overview
11.11.3 Apotex Lacosamide Introduction
11.11.4 Apotex Revenue in Lacosamide Business (2019-2024)
11.11.5 Apotex Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Lacosamide Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Oral tablets
Table 3. Key Players of Oral solution
Table 4. Key Players of Intravenous
Table 5. Global Lacosamide Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Lacosamide Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Lacosamide Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Lacosamide Market Share by Region (2019-2024)
Table 9. Global Lacosamide Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Lacosamide Market Share by Region (2025-2030)
Table 11. Lacosamide Market Trends
Table 12. Lacosamide Market Drivers
Table 13. Lacosamide Market Challenges
Table 14. Lacosamide Market Restraints
Table 15. Global Lacosamide Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Lacosamide Market Share by Players (2019-2024)
Table 17. Global Top Lacosamide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lacosamide as of 2023)
Table 18. Ranking of Global Top Lacosamide Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Lacosamide Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Lacosamide Product Solution and Service
Table 22. Date of Enter into Lacosamide Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Lacosamide Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Lacosamide Revenue Market Share by Type (2019-2024)
Table 26. Global Lacosamide Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Lacosamide Revenue Market Share by Type (2025-2030)
Table 28. Global Lacosamide Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Lacosamide Revenue Market Share by Application (2019-2024)
Table 30. Global Lacosamide Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Lacosamide Revenue Market Share by Application (2025-2030)
Table 32. North America Lacosamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Lacosamide Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Lacosamide Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Lacosamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Lacosamide Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Lacosamide Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Lacosamide Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Lacosamide Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Lacosamide Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Lacosamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Lacosamide Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Lacosamide Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Lacosamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Lacosamide Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Lacosamide Market Size by Country (2025-2030) & (US$ Million)
Table 47. UCB Company Detail
Table 48. UCB Business Overview
Table 49. UCB Lacosamide Product
Table 50. UCB Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 51. UCB Recent Development
Table 52. Teva Company Detail
Table 53. Teva Business Overview
Table 54. Teva Lacosamide Product
Table 55. Teva Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 56. Teva Recent Development
Table 57. Amneal Pharmaceuticals Company Detail
Table 58. Amneal Pharmaceuticals Business Overview
Table 59. Amneal Pharmaceuticals Lacosamide Product
Table 60. Amneal Pharmaceuticals Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 61. Amneal Pharmaceuticals Recent Development
Table 62. MSN Laboratories Company Detail
Table 63. MSN Laboratories Business Overview
Table 64. MSN Laboratories Lacosamide Product
Table 65. MSN Laboratories Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 66. MSN Laboratories Recent Development
Table 67. Alembic Pharma Company Detail
Table 68. Alembic Pharma Business Overview
Table 69. Alembic Pharma Lacosamide Product
Table 70. Alembic Pharma Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 71. Alembic Pharma Recent Development
Table 72. Glenmark Company Detail
Table 73. Glenmark Business Overview
Table 74. Glenmark Lacosamide Product
Table 75. Glenmark Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 76. Glenmark Recent Development
Table 77. Aurobindo Pharma Company Detail
Table 78. Aurobindo Pharma Business Overview
Table 79. Aurobindo Pharma Lacosamide Product
Table 80. Aurobindo Pharma Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 81. Aurobindo Pharma Recent Development
Table 82. Accord Healthcare Company Detail
Table 83. Accord Healthcare Business Overview
Table 84. Accord Healthcare Lacosamide Product
Table 85. Accord Healthcare Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 86. Accord Healthcare Recent Development
Table 87. Mylan Company Detail
Table 88. Mylan Business Overview
Table 89. Mylan Lacosamide Product
Table 90. Mylan Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 91. Mylan Recent Development
Table 92. Sun Pharma Company Detail
Table 93. Sun Pharma Business Overview
Table 94. Sun Pharma Lacosamide Product
Table 95. Sun Pharma Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 96. Sun Pharma Recent Development
Table 97. Apotex Company Detail
Table 98. Apotex Business Overview
Table 99. Apotex Lacosamide Product
Table 100. Apotex Revenue in Lacosamide Business (2019-2024) & (US$ Million)
Table 101. Apotex Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Lacosamide Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Lacosamide Market Share by Type: 2023 VS 2030
Figure 3. Oral tablets Features
Figure 4. Oral solution Features
Figure 5. Intravenous Features
Figure 6. Global Lacosamide Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Lacosamide Market Share by Application: 2023 VS 2030
Figure 8. Adults Case Studies
Figure 9. Pediatric patients Case Studies
Figure 10. Lacosamide Report Years Considered
Figure 11. Global Lacosamide Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Lacosamide Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Lacosamide Market Share by Region: 2023 VS 2030
Figure 14. Global Lacosamide Market Share by Players in 2023
Figure 15. Global Top Lacosamide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lacosamide as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Lacosamide Revenue in 2023
Figure 17. North America Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Lacosamide Market Share by Country (2019-2030)
Figure 19. United States Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Lacosamide Market Share by Country (2019-2030)
Figure 23. Germany Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Lacosamide Market Share by Region (2019-2030)
Figure 31. China Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Lacosamide Market Share by Country (2019-2030)
Figure 39. Mexico Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Lacosamide Market Share by Country (2019-2030)
Figure 43. Turkey Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Lacosamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. UCB Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 46. Teva Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 47. Amneal Pharmaceuticals Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 48. MSN Laboratories Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 49. Alembic Pharma Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 50. Glenmark Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 51. Aurobindo Pharma Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 52. Accord Healthcare Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 53. Mylan Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 54. Sun Pharma Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 55. Apotex Revenue Growth Rate in Lacosamide Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
